Direxion Daily Biotech Top 5 Bull 2X ETF

ProShare Advisors Increases Gilead Stake by 39.1% in Q4, Total Holdings Reach 2.2 Million Shares

Gilead Sciences Chief Communications Officer Johanna Mercier Sells Nearly 28k Shares for $3.55M

Truist Financial Cuts Regeneron Price Target, Sending Shares Gap Down

Regeneron's fianlimab combination fails Phase 3, shares plunge over 11%

Regeneron Partners with Parabilis for $125M Deal to Advance Antibody Conjugates

Gilead Sciences Focuses on HIV Growth and Expands Oncology and Inflammation Pipeline via Acquisitions

Regeneron Provides Update on Phase 3 Trial of Fianlimab Combination for Melanoma

Gilead Sciences Prices $3 Billion Senior Unsecured Bond Offering

Gilead's Yeztugo Revenues Surged 73% QoQ, Exceeding Market Expectations

Daiwa Securities Downgrades Amgen's Target Price to $390.00

WHO Procurement Mechanism Selects South African Lab to Produce AIDS Generic Drug

Amgen Advances Obesity Drug MariTide to Phase III Trial

Analysts at Cantor Fitzgerald and Bernstein Give Buy Rating to Gilead Sciences

Argenx SE Receives FDA Approval to Expand Indications for MG Drugs

Barclays Maintains Buy Rating on arGEN X with a Price Target of 900 Euros

Jefferies Analyst Reiterates Buy Rating on arGEN X

Gilead Sciences released FY2026 Q1 earnings on May 7 After-Market EST, actual revenue USD 6.96 B (forecast USD 6.929 B), actual EPS USD 1.61 (forecast USD 1.5805)

Gilead Sciences Raises 2026 Sales Forecast

Gilead Sciences reports Q1 product sales of $6.946 billion

Argenx released FY2026 Q1 earnings on May 7 During-Market (EST), actual revenue USD 1.313 B (forecast USD 1.284 B), actual EPS USD 5.5199 (forecast USD 5.0946)

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

ALNY

LABU

IBBQ

TBXU

Alnylam Pharmaceuticals CFO Jeff Poulton expressed confidence in the company's TTR revenue guidance, despite a slower growth rate in Q1. Key drivers include access, international launches, and prescriber expansion. Alnylam aims for TTR revenue of $4.4 to $4.7 billion, primarily from AMVUTTRA, with Q1 revenue at $910 million, showing over 150% year-over-year growth. The company is focused on increasing prescriber numbers and expects improved performance in Q2. Poulton also discussed competition and the potential for combination therapies as tafamidis approaches generic status in 2031.

Market Beat

Alnylam Pharma

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

iShares Biotechnology ETF

Ark Genomic Revolution ETF

SPDR S&P Biotech

iShares US Pharma

VG Health

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

iShares Global Healthcare

ALPS Medical Breakthrough

Bank of America

Argenx

Ionis Pharma

AstraZeneca

AstraZeneca PLC

Pfizer

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build

ARVN

RIGL

Rigel Pharmaceuticals has entered an exclusive global license agreement with Arvinas and Pfizer to commercialize Veppanu (vepdegestrant), the first FDA-approved Protac for cancer therapy. This agreement expands Rigel's oncology portfolio, targeting ESR1 mutations in ER-positive breast cancer. Rigel will pay $70 million upfront and up to $40 million for development activities, with royalties on sales. Veppanu, approved on May 1, 2026, shows significant efficacy in clinical trials, reducing disease progression risk by 43%. The deal is expected to close in mid-June 2026, pending antitrust clearance.

- Rigel Pharmaceuticals has signed an exclusive global license agreement with Arvinas and Pfizer to commercialize Veppanu, an FDA-approved Protac for advanced breast cancer.  
- This revolutionary therapy targets the estrogen receptor, aiming to degrade mutant receptors that contribute to treatment resistance, and has shown a 43% reduction in disease progression risk in clinical trials.  
- Rigel will pay $70 million upfront and up to $40 million for development activities, while retaining exclusive rights to the drug, which is expected to enhance Rigel's oncology portfolio significantly.

Pharmexec

Arvinas

Rigel Pharma

<![CDATA[Rigel Pharmaceuticals Enters $85 Million Agreement for Exclusive Global Rights to Veppanu]]>

Pfizer and Arvinas have licensed global rights for VEPPANU, the first FDA-approved oral PROTAC for advanced breast cancer, to Rigel Pharmaceuticals. This deal allows Pfizer and Arvinas to receive royalties and milestone payments while focusing on their oncology pipelines. The agreement enhances Pfizer's oncology strategy and offers investors potential future revenue streams. However, risks include debt coverage and a dividend yield not well supported by earnings. Pfizer's stock trades below analyst targets and fair value estimates, with recent share price declines.

- Pfizer and Arvinas have licensed global rights for VEPPANU to Rigel Pharmaceuticals, the first oral PROTAC approved for advanced breast cancer.  
- This agreement allows Pfizer and Arvinas to earn royalties while focusing on their oncology and PROTAC pipelines, as VEPPANU will develop under Rigel's commercial efforts.  
- Investors are urged to monitor the implications of this deal on Pfizer's oncology strategy and capital allocation, amid concerns over debt coverage and dividend sustainability.

Simplywall

Pfizer PROTAC Licensing Deal With Rigel Adds Royalties To Valuation Story

Can a push into oncology and next-generation therapies make up for Pfizer's post-Covid letdown?

Is Pfizer a buy, sell, or hold in 2026?

4503

ALPMY

The Scottish Medicines Consortium has recommended the reimbursement of enfortumab vedotin with pembrolizumab for adults with unresectable or metastatic urothelial cancer. This decision allows access to a treatment that significantly improves overall survival through the NHS. The EV-302 phase 3 trial showed a median overall survival of 33.8 months for the combination compared to 15.9 months for chemotherapy. Experts believe this combination will reshape first-line treatment for advanced bladder cancer patients in Scotland.

PharmaTimes

Astellas Pharma Inc.

Astellas Pharma

SMC backs first-line metastatic bladder cancer combination after trial results

New data analyses presented at Heart Failure 2026 highlight the clinical benefits of Vutrisiran as a first-line treatment for ATTR-CM patients, including those with a high disease burden. This information is relevant for ALNY stock news.

StockTitan

New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden | ALNY Stock News

The article discusses three stocks poised to benefit from AI in healthcare: Pfizer, Tempus AI, and Medtronic. Pfizer, with a market cap of $146.4 billion, focuses on drug development and AI-supported R&D, despite facing revenue declines. Tempus AI, valued at $9 billion, leverages AI for precision medicine but struggles with profitability. Medtronic, worth $97.8 billion, combines AI with medical devices, showing strong growth potential and a 3.73% dividend yield. Each company presents unique opportunities and risks in the evolving healthcare landscape driven by AI.

- The article discusses the integration of AI in healthcare, focusing on how companies like Pfizer, Tempus AI, and Medtronic are leveraging AI for improved diagnostics and treatment.  
- Pfizer, with a market cap of US$146.4 billion, is enhancing R&D through AI while facing revenue declines and dividend pressures.  
- Tempus AI and Medtronic are also highlighted for their innovative approaches, but they face challenges such as significant losses and external funding reliance.

Medtronic

Tempus AI

iShares US Healthcare Providers

iShares US Medical Devices

SPDR S&P Health Equip

iShares Genomics Immunology and Healthcare ETF

If AI Reshapes Healthcare, These Three Stocks Could Lead

Securian Asset Management Inc. has reduced its holdings in Pfizer Inc. by 43.7%, selling 119,974 shares during the 4th quarter, leaving it with 154,605 shares valued at $3.85 million. Other institutional investors have also adjusted their stakes in Pfizer. Recent analyst coverage has been positive, with Scotiabank initiating a Buy rating and Erste Group raising FY2026 EPS estimates. However, Pfizer faced setbacks with the termination of early-stage cancer trials, which may impact investor sentiment. The stock opened at $25.65, with a market cap of $146.17 billion and a P/E ratio of 19.58.

- Securian Asset Management Inc. reduced its holdings in Pfizer Inc. by 43.7% during the 4th quarter, owning 154,605 shares worth $3,850,000 after selling 119,974 shares.  
- Various institutional investors have adjusted their stakes in Pfizer, with Horizon Financial Services LLC increasing its position by 174.8% during the same period.  
- Analysts generally maintain a "Hold" rating on Pfizer, with a mixture of positive and negative sentiments regarding recent performance and ongoing trials affecting the stock's outlook.

Securian Asset Management Inc. Sells 119,974 Shares of Pfizer Inc. $PFE

MRNA

NVAX

Novavax Inc. (NASDAQ: NVAX) shares are seeing increased trading activity following Moderna Inc.'s (NASDAQ: MRNA) announcement of early-stage research on hantavirus vaccines. Despite recent cruise ship deaths linked to a virus, health experts deem the risk to public health minimal. Moderna is collaborating with the U.S. Army Medical Research Institute on this vaccine development. Meanwhile, Pfizer and BioNTech have paused their COVID vaccine trial due to low enrollment.

Unusual Whales

Moderna

Novavax

BioNTech SE

What's Going On With Novavax Stock On Friday?

The FDA has issued an untitled letter to Alnylam regarding its Amvuttra website, claiming it presents misleading efficacy data. The agency criticized the use of open-label trial results, stating that the lack of a true placebo group after 3.5 years introduces bias. Despite a caveat on the website, the FDA concluded that the claims misbrand Amvuttra, violating the Federal Food, Drug, and Cosmetic Act. Alnylam has 15 working days to respond, and this is the second untitled letter the company has received from the FDA in recent months.

Direxion Daily Biotech Top 5 Bull 2X ETF(TBXU.US)

Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build

<![CDATA[Rigel Pharmaceuticals Enters $85 Million Agreement for Exclusive Global Rights to Veppanu]]>

Pfizer PROTAC Licensing Deal With Rigel Adds Royalties To Valuation Story

Is Pfizer a buy, sell, or hold in 2026?

SMC backs first-line metastatic bladder cancer combination after trial results